Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.
about
May the Best Molecule Win: Competition ESI Mass SpectrometryA ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome coreReaction of the Anticancer Organometallic Ruthenium Compound, [(eta-p-Cymene)Ru(ATSC)Cl]PF(6) with Human Serum AlbuminReactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSOrganometallic anticancer compoundsBiological activity and binding properties of [Ru(II)(dcbpy)2Cl2] complex to bovine serum albumin, phospholipase A2 and glutathione.Automatic assignment of metal-containing peptides in proteomic LC-MS and MS/MS data sets.Fast and slow versus strong and weak metal-DNA binding: consequences for anti-cancer activity.Organometallic compounds: an opportunity for chemical biology?Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity.The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549).Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies.Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex.[Au2(phen(2Me))2(μ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties.The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.Insights into the binding sites of organometallic ruthenium anticancer compounds on peptides using ultra-high resolution mass spectrometry.Mass-spectrometric characterization of cisplatin binding sites on native and denatured ubiquitin.Computational properties of η6-toluene and η6-trifluorotoluene half-sandwich Ru(II) anticancer complexes.Structural analysis of ruthenium-arene complexes using ion mobility mass spectrometry, collision-induced dissociation, and DFT.Mass spectrometric strategies to improve the identification of Pt(II)-modification sites on peptides and proteins.Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action† †Electronic supplementary information (ESI) available: Experimental, crystallographic, biological and mass spectrometric data, full list of prTarget profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action.Controlling with light the interaction between trans-tetrapyridyl ruthenium complexes and an oligonucleotide.Identification of binding sites of cisplatin to human copper chaperone protein Cox17 by high-resolution FT-ICR-MS.Sequence-dependent attack on peptides by photoactivated platinum anticancer complexes.Efficiently Detecting Metallodrug-Protein Adducts: Ion Trap versus Time-of-Flight Mass Analyzers
P2860
Q26779012-15D470A6-F2F4-4FA9-8898-0A0E1D88FD22Q27666776-DF3F5AEE-E8A9-4811-8015-B7AD0DC1B4D1Q34025532-4CE63031-9040-43EC-A787-5F3EA9DF76C2Q34394993-F3060722-B76E-403D-9346-0754B22A5D01Q34476685-3EBF9DD4-8EF3-498E-B812-D6E843E716E8Q36102249-413DCD6C-7FD1-4484-AB84-3A03F4B5690AQ36373894-8F36A20F-F92D-4C2C-80E0-35A2F223CF3FQ38001300-B3397050-5E7F-4AFF-8F67-7D76F753E494Q38012429-5C2CCB1C-36D8-4730-B6E6-1DBC55A9A761Q38105454-DC7DDB16-2D47-421D-ABD4-F5F6200DF34EQ38287806-51C24946-00DC-4C97-8919-DA1DE202F924Q39000197-DBFE1812-9891-4E49-BB14-ED582B0D644EQ39121561-F3DC8375-3A43-444B-8F38-12BAFA8317D6Q39146826-7E365520-48F6-414B-BA5F-CD08CE387612Q39155790-8E3F3A1D-6C69-4AA7-AAEA-E958F0148B79Q39159067-81C6C0C2-4351-4F73-9550-F74DE5A8A948Q42874055-104FAF17-AA01-4F6F-A0B1-60D4371C1E04Q43729194-EA93B8EC-5D0D-4C27-BA6A-758022F59E65Q44963722-165CE08D-792B-432D-884F-521F2361DC83Q46014374-66EC4453-CEB3-4F45-9C49-336AF042EAC7Q46595407-B4F7BE1C-5992-427D-A572-486812E2119AQ46892086-DB1580DD-95B5-42CC-9BC3-D98EFD869ADFQ47159745-EB6B6EFD-8E76-4113-8913-4B7C025D79EFQ47196925-D90CCD48-A537-44BC-B17E-7CBF9252D65AQ49915461-DE0D1FD0-3C57-47C9-AC29-C7E5CCC75C71Q51193190-3EB8CC84-001A-4B47-9C91-E3330636BBF5Q55322316-0AC81CF1-EBEF-4A34-9C2F-8A6E1B2B32FAQ57693530-9D779809-A908-4946-8A68-45F9D6E14C91
P2860
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Exploring metallodrug-protein ...... nometallic ruthenium compound.
@en
Exploring metallodrug-protein ...... nometallic ruthenium compound.
@nl
type
label
Exploring metallodrug-protein ...... nometallic ruthenium compound.
@en
Exploring metallodrug-protein ...... nometallic ruthenium compound.
@nl
prefLabel
Exploring metallodrug-protein ...... nometallic ruthenium compound.
@en
Exploring metallodrug-protein ...... nometallic ruthenium compound.
@nl
P50
P1476
Exploring metallodrug-protein ...... nometallic ruthenium compound.
@en
P2093
Elena Michelucci
Gloriano Moneti
P2888
P304
P356
10.1007/S00775-009-0489-5
P577
2009-03-14T00:00:00Z